Cantor Fitzgerald reiterates Novavax stock rating on partnership success
Cantor Fitzgerald reiterated an Overweight rating on Novavax (NVAX) with a $18.00 price target, citing a $125M milestone payment. NVAX shares trade at $9.40, down 17.76% in a week. The company reported narrower-than-expected Q2 2026 losses and beat revenue forecasts, raising its full-year sales outlook. NVAX focuses on licensing its Nuvaxovid vaccine and Matrix-M adjuvant technology.
How this was made
The 30-second read
Why it matters
The rating and cash milestone could modestly lift NVAX, but broader market focus is elsewhere.
Market read
Small upside catalyst for NVAX; limited broader market effect.
What to watch
Potential competition from Moderna/Merck melanoma trial news could distract investors.
Background
Analyst reiterates rating after milestone payment and Q2 earnings beat.
Ticker impact
Cantor Fitzgerald reiterated an Overweight rating on Novavax and highlighted a $125 million milestone payment and Q2 earnings beat.
likely upward pressure as investors price in the higher target and cash milestone.
The rating change and cash receipt are new analyst-driven catalysts, but the earnings beat was already public.
Market effects
Positive signal for biotech licensing models.
Limited to US biotech investors.
Minor, confined to NVAX shareholders.
Counterpoint
The milestone may be a one‑off and earnings beat modest; price may stay flat.
Key entities
- companyNovavax Inc.
Biotech firm developing vaccines.
- analystCantor Fitzgerald
Equity research firm issuing the rating.




